Categories
Change Password!
Reset Password!
An open observational (MULTINEURO-1) trial was conducted on the safety and efficacy of elevated doses (150 mg) of uridine monophosphate in combination with choline to treat individuals having low back pain.
Clinicians now would be able to use uridine
monophosphate (high doses) in combination with choline (the supplement
neurouridine) to treat patients with non-specific low back pain.
An open observational (MULTINEURO-1) trial was conducted on
the safety and efficacy of elevated doses (150 mg) of uridine
monophosphate in combination with
choline to treat individuals having low back pain.
The study recruited 50 patients suffering from non-specific
low back pain. For evaluating the efficacy, the following scales were utilized:
(a) the painDETECT questionnaire (PD-Q), (b) the Hospital Anxiety and
Depression Scale (HADS), (c) Visual Analogue scale (VAS), (d) the Roland-Morris
Low Back Pain and Disability Questionnaire (RMQ), and (e) the Pittsburgh Sleep
Quality Index
A
greater decline in the pain intensity was noted in the main group than in the
comparison group. The results of PD-Q illustrated a remarkable decline in the
severity of the neuropathic component of pain in the treatment group. The RMQ
revealed signs of improved functional status.
High doses of uridine monophosphate in combination with
supplement neurouridine appear to yield satisfactory outcomes in patients with
nonspecific acute low back pain.
Journal of Neurology and Psychiatry
[The results of an open observational study on multimodal effects of the efficacy and safety of supplement neurouridine in patients with nonspecific low back pain (MULTINEURO-1)]
E Z Yakupov et al.
Comments (0)